Alternative Financing Mechanisms
This article was originally published in Start Up
Executive Summary
With the markets down, it's time to explore alternatives to straight equity deals for public companies: PIPEs, equity lines of credit, convertible debt, and "toxic preferred" securities.
You may also be interested in...
Horses for Courses: Why VCs Stick with Private, Not Public Investing
With public markets up but private equity markets still in the doldrums, why don't VCs shift their strategies to favor purchasing public biotechs? They have--a bit. But public investing doesn't exploit a VC's competitive advantages or justify the relatively high management fees they charge.
Financing Alternatives for Public Companies
The sudden closing of a stock market window for public offerings is not a happy event for companies caught in the midst of the offering process. So what should a company do in this situation? Advice of Counsel explores financing alternatives.
Why Clinical Trials Fail Unexpectedly
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.